Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:MIRM NASDAQ:PTCT NASDAQ:RYTM NASDAQ:SNDX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMIRMMirum Pharmaceuticals$107.13$98.70$47.89▼$114.99$6.53B0.5751,045 shs1.58 million shsPTCTPTC Therapeutics$78.98$71.37$43.17▼$87.50$6.55B0.561.71 million shs2.86 million shsRYTMRhythm Pharmaceuticals$96.79$88.70$60.80▼$122.20$6.63B1.91711,999 shs1.56 million shsSNDXSyndax Pharmaceuticals$19.00$20.46$8.59▼$25.59$1.68B0.381.87 million shs3.99 million shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMIRMMirum Pharmaceuticals0.00%+7.83%+10.50%+21.04%+110.89%PTCTPTC Therapeutics0.00%+5.11%+11.21%+20.95%+56.61%RYTMRhythm Pharmaceuticals0.00%+9.52%+6.79%+10.68%+57.43%SNDXSyndax Pharmaceuticals0.00%+4.11%-5.61%-21.58%+96.08%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMIRMMirum Pharmaceuticals$107.13$98.70$47.89▼$114.99$6.53B0.5751,045 shs1.58 million shsPTCTPTC Therapeutics$78.98$71.37$43.17▼$87.50$6.55B0.561.71 million shs2.86 million shsRYTMRhythm Pharmaceuticals$96.79$88.70$60.80▼$122.20$6.63B1.91711,999 shs1.56 million shsSNDXSyndax Pharmaceuticals$19.00$20.46$8.59▼$25.59$1.68B0.381.87 million shs3.99 million shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMIRMMirum Pharmaceuticals0.00%+7.83%+10.50%+21.04%+110.89%PTCTPTC Therapeutics0.00%+5.11%+11.21%+20.95%+56.61%RYTMRhythm Pharmaceuticals0.00%+9.52%+6.79%+10.68%+57.43%SNDXSyndax Pharmaceuticals0.00%+4.11%-5.61%-21.58%+96.08%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceMIRMMirum Pharmaceuticals 2.93Moderate Buy$139.8030.50% UpsidePTCTPTC Therapeutics 2.71Moderate Buy$91.3615.67% UpsideRYTMRhythm Pharmaceuticals 2.83Moderate Buy$133.1337.54% UpsideSNDXSyndax Pharmaceuticals 2.92Moderate Buy$42.55123.92% UpsideCurrent Analyst Ratings BreakdownLatest SNDX, RYTM, PTCT, and MIRM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/17/2026RYTMRhythm Pharmaceuticals TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/16/2026RYTMRhythm Pharmaceuticals Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$143.00 ➝ $151.006/15/2026RYTMRhythm Pharmaceuticals Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$133.006/15/2026MIRMMirum Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/15/2026RYTMRhythm Pharmaceuticals Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$144.00 ➝ $155.006/15/2026MIRMMirum Pharmaceuticals CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform6/15/2026MIRMMirum Pharmaceuticals CLSASubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$146.006/15/2026MIRMMirum Pharmaceuticals Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Outperform$140.00 ➝ $146.006/12/2026SNDXSyndax Pharmaceuticals UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/12/2026SNDXSyndax Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$40.006/11/2026MIRMMirum Pharmaceuticals Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$140.00 ➝ $150.00(Data available from 6/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookMIRMMirum Pharmaceuticals$521.31M12.53$0.05 per share2,101.45$6.12 per share17.50PTCTPTC Therapeutics$1.73B3.79$8.78 per share9.00($2.56) per share-30.85RYTMRhythm Pharmaceuticals$189.76M34.95N/AN/A$2.08 per share46.53SNDXSyndax Pharmaceuticals$172.35M9.77N/AN/A$0.74 per share25.68Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateMIRMMirum Pharmaceuticals-$23.36M-$13.61N/A465.78N/A-140.24%-11.28%-3.84%7/30/2026 (Estimated)PTCTPTC Therapeutics$682.64M-$2.33N/A37.433.63-22.58%-362.45%-6.76%8/6/2026 (Estimated)RYTMRhythm Pharmaceuticals-$196.54M-$3.13N/AN/AN/A-93.33%-203.25%-44.99%8/4/2026 (Estimated)SNDXSyndax Pharmaceuticals-$285.42M-$2.79N/AN/AN/A-111.88%-256.65%-45.25%8/3/2026 (Estimated)Latest SNDX, RYTM, PTCT, and MIRM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026PTCTPTC Therapeutics-$0.45-$0.03+$0.42-$0.03$217.42 million$272.55 million5/6/2026Q1 2026MIRMMirum Pharmaceuticals-$0.75-$13.43-$12.68-$13.43$148.21 million$159.88 million5/5/2026Q1 2026RYTMRhythm Pharmaceuticals-$0.86-$0.83+$0.03-$0.83$55.78 million$60.11 million4/30/2026Q1 2026SNDXSyndax Pharmaceuticals-$0.59-$0.48+$0.11-$0.48$69.76 million$64.86 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthMIRMMirum PharmaceuticalsN/AN/AN/AN/AN/APTCTPTC TherapeuticsN/AN/AN/AN/AN/ARYTMRhythm PharmaceuticalsN/AN/AN/AN/AN/ASNDXSyndax PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioMIRMMirum Pharmaceuticals1.282.091.99PTCTPTC TherapeuticsN/A2.442.36RYTMRhythm PharmaceuticalsN/A4.173.89SNDXSyndax Pharmaceuticals8.265.475.06Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipMIRMMirum PharmaceuticalsN/APTCTPTC TherapeuticsN/ARYTMRhythm PharmaceuticalsN/ASNDXSyndax PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipMIRMMirum Pharmaceuticals8.32%PTCTPTC Therapeutics5.50%RYTMRhythm Pharmaceuticals5.90%SNDXSyndax Pharmaceuticals4.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableMIRMMirum Pharmaceuticals14060.98 million55.91 millionOptionablePTCTPTC Therapeutics1,41082.95 million78.39 millionOptionableRYTMRhythm Pharmaceuticals14068.53 million64.49 millionOptionableSNDXSyndax Pharmaceuticals11088.61 million84.36 millionOptionableSNDX, RYTM, PTCT, and MIRM HeadlinesRecent News About These CompaniesIshara Investments LP Takes Position in Syndax Pharmaceuticals, Inc. $SNDXJune 18 at 6:12 AM | marketbeat.comElmind Capital LP Purchases New Stake in Syndax Pharmaceuticals, Inc. $SNDXJune 18 at 5:52 AM | marketbeat.comEversept Partners LP Decreases Stock Holdings in Syndax Pharmaceuticals, Inc. $SNDXJune 18 at 5:36 AM | marketbeat.comSyndax Pharmaceuticals, Inc. $SNDX Shares Sold by Catalio Capital Management LPJune 18 at 5:26 AM | marketbeat.comApis Capital Advisors LLC Acquires 86,000 Shares of Syndax Pharmaceuticals, Inc. $SNDXJune 18 at 3:44 AM | marketbeat.comSyndax Pharmaceuticals (SNDX) Gets a Buy from GuggenheimJune 14, 2026 | theglobeandmail.comSyndax Pharmaceuticals (SNDX) Is Up 5.2% After Strong All-Oral Revuforj SAVE Trial Data - What's ChangedJune 14, 2026 | finance.yahoo.comEventide Asset Management LLC Has $26.01 Million Stock Holdings in Syndax Pharmaceuticals, Inc. $SNDXJune 14, 2026 | marketbeat.comVoss Capital LP Buys Shares of 125,000 Syndax Pharmaceuticals, Inc. $SNDXJune 13, 2026 | marketbeat.comSyndax Pharmaceuticals (NASDAQ:SNDX) CMO Sells $566,602.90 in StockJune 13, 2026 | insidertrades.comRhenman & Partners Asset Management AB Sells 87,000 Shares of Syndax Pharmaceuticals, Inc. $SNDXJune 13, 2026 | marketbeat.comSyndax Announces Publication of SAVE Data on Revuforj® (revumenib) in Combination with Decitabine/Cedazuridine and Venetoclax in Relapsed/Refractory NPM1m, KMT2Ar, and NUP98r ...June 11, 2026 | finance.yahoo.comSyndax Pharmaceuticals: The Duration Expansion Story Is Being UnderpricedJune 11, 2026 | seekingalpha.comSyndax Showcases Revuforj® (revumenib) Clinical Activity in Multiple Acute Leukemia Subtypes and Settings at EHA 2026June 11, 2026 | globenewswire.comSyndax Announces Publication of SAVE Data on Revuforj® (revumenib) in Combination with Decitabine/Cedazuridine and Venetoclax in Relapsed/Refractory NPM1m, KMT2Ar, and NUP98r AML in the Journal of Clinical OncologyJune 11, 2026 | globenewswire.comStifel Nicolaus Sticks to Their Buy Rating for Syndax Pharmaceuticals (SNDX)June 10, 2026 | theglobeandmail.comSyndax Pharmaceuticals, Inc. (SNDX) Shareholder/Analyst Call Prepared Remarks TranscriptJune 10, 2026 | seekingalpha.comTraders Buy High Volume of Syndax Pharmaceuticals Call Options (NASDAQ:SNDX)June 10, 2026 | americanbankingnews.comSyndax Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:SNDX)June 9, 2026 | marketbeat.comSyndax Pharmaceuticals, Inc. (SNDX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptJune 8, 2026 | seekingalpha.comSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)June 4, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSNDX, RYTM, PTCT, and MIRM Company DescriptionsMirum Pharmaceuticals NASDAQ:MIRM$107.13 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$107.04 -0.08 (-0.08%) As of 06/18/2026 04:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.PTC Therapeutics NASDAQ:PTCT$78.98 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$78.91 -0.07 (-0.09%) As of 06/18/2026 05:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.Rhythm Pharmaceuticals NASDAQ:RYTM$96.79 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$98.35 +1.56 (+1.61%) As of 06/18/2026 06:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.Syndax Pharmaceuticals NASDAQ:SNDX$19.00 0.00 (0.00%) As of 06/18/2026 04:00 PM EasternSyndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/15 - 06/19 Satellogic Is Tiny But Its Revenue Growth Is Hard to Ignore Aehr Spikes on New Order, But Has Stock Gotten Ahead of Itself? Why Kroger’s Pullback Could Be a Gift for Patient Investors Credo Technologies Accelerates AI—Its Stock Price Will Follow Why Rocket Lab’s Nasdaq-100 Moment Could Change the Story Why Palantir’s Google Cloud Deal Could Change the Debate VMware: Broadcom's Second Biggest Business Set to Accelerate Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
